Bright Peak Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
57
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$90M
- Investors
-
12
Bright Peak Therapeutics General Information
Description
Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. The company develops immuno-cytokines with pharmacological properties that allow tissue and cell-specific targeting through cytokine payload with the added potential for enhanced efficacy, enabling doctors to improve treatment outcomes and quality of life for patients.
Contact Information
Website
www.brightpeaktx.comCorporate Office
- Switzerland Innovation Park Basel Area
- Hegenheimermattweg 167 D
- 4123 Allschwil
- Switzerland
Corporate Office
- Switzerland Innovation Park Basel Area
- Hegenheimermattweg 167 D
- 4123 Allschwil
- Switzerland
Bright Peak Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 11-Jun-2024 | $90M | Completed | Pre-Clinical Trials | ||
| 5. Early Stage VC (Series B) | 10-Jun-2021 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 28-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 11-Dec-2018 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 14-Dec-2017 | Completed | Startup | |||
| 1. University Spin-Out | 14-Dec-2017 | Completed | Startup |
Bright Peak Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Bright Peak Therapeutics Comparisons
Industry
Financing
Details
Bright Peak Therapeutics Competitors (1)
One of Bright Peak Therapeutics’s competitors is CytoAgents, a Venture Capital-Backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA |
Bright Peak Therapeutics Patents
Bright Peak Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026139739-A1 | Dual binding compositions targeting vegfa and pd-1 | Pending | 27-Dec-2024 | ||
| WO-2026083296-A1 | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains | Pending | 16-Oct-2024 | ||
| US-20260139053-A1 | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains | Pending | 16-Oct-2024 | ||
| US-20260184792-A1 | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains | Pending | 16-Oct-2024 | ||
| WO-2026083295-A1 | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains | Pending | 16-Oct-2024 | C07K16/2818 |
Bright Peak Therapeutics Signals
Bright Peak Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| KB Investment | Venture Capital | Minority | ||
| Northleaf Capital Partners | PE/Buyout | Minority | ||
| Venrock | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority |
Bright Peak Therapeutics FAQs
-
When was Bright Peak Therapeutics founded?
Bright Peak Therapeutics was founded in 2017.
-
Where is Bright Peak Therapeutics headquartered?
Bright Peak Therapeutics is headquartered in Allschwil, Switzerland.
-
What is the size of Bright Peak Therapeutics?
Bright Peak Therapeutics has 57 total employees.
-
What industry is Bright Peak Therapeutics in?
Bright Peak Therapeutics’s primary industry is Drug Discovery.
-
Is Bright Peak Therapeutics a private or public company?
Bright Peak Therapeutics is a Private company.
-
What is Bright Peak Therapeutics’s current revenue?
The current revenue for Bright Peak Therapeutics is .
-
How much funding has Bright Peak Therapeutics raised over time?
Bright Peak Therapeutics has raised $244M.
-
Who are Bright Peak Therapeutics’s investors?
Johnson & Johnson JJDC, KB Investment, Northleaf Capital Partners, Venrock, and Alexandria Venture Investments are 5 of 12 investors who have invested in Bright Peak Therapeutics.
-
Who are Bright Peak Therapeutics’s competitors?
CytoAgents is a competitor of Bright Peak Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process